Trial Profile
An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms BRIGHT
- Sponsors Cephalon; Teva Branded Pharmaceutical Products R&D
- 27 Feb 2019 Results assessing long term follow up data of BRIGHT study published in the Journal of Clinical Oncology
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.
- 25 May 2017 According to a Sarah Cannon Research Institute media release, data from the study will be presented at the American Society of Clinical Oncology's 2017 Annual Meeting.